Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

Comprehensive Review of Pharmaceutical Advancements, Patient Care Models, and Drug Safety

Sari Mohammed Alhawiti[1], Abdullah Salman Alatawi[2], Naif Shayish Alsharari[3], Hamad Saad Albalawi[4], Ziyad Saleh S Alsharqawi[5], Amal Aydh Albaqami[6], Abdulaziz Saleh Albalawi[7], Ahmed Abdulrahman Alfaqeih[8], Hani Saeed Hamoud Albalawi[9], Adnan Aed Baraka Alenezi[10]

Abstract

This review disseminates new developments in this industry, changes in the care delivery systems, and innovations in drug safety. Pharmaceuticals have brought innovative changes within their field of drug formation, new theories regarding medicine for individuals, and introducing biotechnologies. At the same time, patient care models are changing towards the more integrated and patient-oriented ones. Further, maintaining drug safety continues to be a critical focal point because the complexity of drug therapies continues to increase, and their potential adverse effects need to be minimized. This review, therefore, looks at these interconnections based on current literature, research findings, and case studies in a bid to give an overall vision of the evolution of modern pharmaceuticals and how their advancement impacts the delivery of healthcare.

Keywords: *Pharmaceutical advancements; patient care models; drug safety; personalized medicine; biotechnology; drug development; healthcare delivery; pharmacovigilance.*

Introduction

The industry has witnessed transformations over the past few decades due to technological developments, better research techniques, and knowledge of human bodily systems. High-throughput screening, combinatorial chemistry, genomics, proteomics, pharmacogenomics, and improvements in drug design have all presented hope for improved treatments (Mohammad et al., 2024a; Mohammad et al., 2023a; Mohammad et al, 2024b). However, over the last decades, especially with the emergence of highly effective drug therapies for previously untreatable diseases, drug safety has become a growing concern due to the complexity of modern drugs and their interactions with the human body; clinical pharmacologists have enhanced the pharmacovigilance systems and patient monitoring.

Thus, knowledge-based developments have also resulted in the renewal of the various patient care models. The new trend in patient care models focuses on the vision that patients require more than simple treatment for their ailments. As will be seen in the discussion of the existing models and their linkages with developments in pharmacology, integrating these models to enhance the general performance and clinical outcomes of patients has the benefit of offering solutions to healthcare accessibility, cost, and the elucidation of the ethical issues raised by new therapies. This review aims to review the trends in pharmaceuticals, patient care models, and drug safety in order to understand their influence on current practice.

Literature Review

Pharmaceutical Advancements

[1] Tabuk University, Saudi Arabia; S.alhawiti@ut.edu.sa.
[2] Ministry of Health, Saudi Arabia; Najem906@hotmail.com.
[3] Ministry of Health, Saudi Arabia; naif.s.alsharari@gmail.com.
[4] Ministry of Health, Saudi Arabia; hamad2828@hotmail.com.
[5] Ministry of Health, Saudi Arabia; zss.k.s.a@hotmail.com.
[6] Ministry of Health, Saudi Arabia; Albogmi-amal@hotmail.com.
[7] Ministry of Health, Saudi Arabia; alblawiazoz@gmail.com.
[8] Ministry of Health, Saudi Arabia; Ahmed554553699@gmail.Com.
[9] Ministry of Health, Saudi Arabia; hani7060@icloud.com.
[10] Ministry of Health, Saudi Arabia; aa0552315461@gmail.com.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

Drug Discovery and Biotechnology

Drug discovery has undergone a revolution that has improved in recent years through biotechnology, introducing new therapies that have changed treatments. One such innovation can be categorized under the advancement of vaccines, where the use of mRNA to create vaccines gained popularity during the COVID-19 pandemic. The fast advancement and distribution of vaccines such as the Pfizer-BioNTech and Moderna vaccines revealed the possibility and applicability of the mRNA-based platforms for the fast creation of drugs, setting up an example for subsequent vaccine and treatment studies (Mohammad et al., 2023b; Al-Hawary et al., 2020; Al-Husban et al., 2023). These vaccines were created one year ago, which also brought a revolution in the way of making vaccines due to the flexibility and short time taken in developing such vaccines.

Another example is the other technologies of biotechnology, including the development of highly effective mRNA vaccines, monoclonal antibodies, and gene therapies. Chemotherapy, together with the use of monoclonal antibodies, will target the proteins that help in the growth of cancer cells, like the trastuzumab (Herceptin) used in indicating HER2 positives in breast cancers. Additionally, gene therapies—as used in treating inherited genetic disorders, including sickle cell anemia and beta-thalassemia—present other horizons and frontiers to what is practically achievable in treating hitherto incurable diseases. Also, there are ambitions to perform gene edits like CRISPR, which have increased the possibility of fixing mutations at the gene level and offering permanent treatment for genetic diseases.



(Singh et al., 2016).

Timeline of Pharmaceutical Advancements in Drug Discovery (Bar Chart)

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253



This bar chart highlights key milestones in the history of pharmaceutical advancements, including the introduction of mRNA vaccines, monoclonal antibodies, CAR-T cell therapy, and CRISPR gene editing (Muheem et al., 2016; Al-Nawafah et al., 2022; Alolayyan et al., 2018; Eldahamsheh, 2021).

Personalized Medicine

The advancement in personalized medication has brought drastic changes in the drug industry. Personalized medicine tries to improve the effectiveness of pharmaceuticals employed in handling diseases and to reduce side effects, all through the use of human genetic type. Personalization is most relevant in cases of onomatology, which discusses different cancers and shows that patients have considerably different genetics. For instance, the production of trastuzumab—a drug that attacks the HER2 gene in breast cancer—gives better survival outcomes in patients with the gene. Likewise, olaparib, a selective inhibitor of BRCA1/2 mutations, is compatible with increased treatment effectiveness in ovarian cancer patients who are carriers of those aberrations. Instead of a general treatment plan for all patients, personalized medicine can show the precise genre of genetic mutations that can cause diseases and directly address such problems.

Personalized Medicine Approaches in Oncology

Patient Care Models: The new patient-oriented care model is rapidly gaining popularity because, in its base, real patients's preferences, needs, and values are considered. It emphasizes the participation of citizens, especially patients, in decision-making and planning of their treatment services. Research has established that patients' value-based care enhances patients' satisfaction, their health, and the level of compliance they have toward their prescriptions. It informs patients and increases the general degree of decision-making, allowing us to disseminate authority and create a team-based environment where healthcare professionals are members of the decision rather than strictly directing the situation. Also, patient-centered models enhance the delivery of health care according to individual

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253



Impact of Patient-Centered Care on Patient Satisfaction (Pie Chart)



This pie chart depicts the significant positive impact of patient-centered care on patient satisfaction, highlighting key metrics such as adherence to treatment, healthcare outcomes, and patient satisfaction levels(Alhassan & Ahmed 2016)..

Telemedicine and Digital Health: : Two areas where digital health solutions have been instrumental in removing barriers to care include telemedicine, where care has been taken to people who, due to geographical location, could not be accessed. These technologies help in telemedicine, which involves doing

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

physical checkups, health consultations, and development of care plans over the Internet to help patients access healthcare services at home. Because of the COVID-19 pandemic, the use of telemedicine increased dramatically as healthcare organizations transitioned to telecommunication to reduce COVID-19 exposure. Telemedicine not only maintains continuing care but also enables a large number of cases of chronic diseases by using various means of communication. Nevertheless, the use of these tools in learning is bound by attributes like internet connection, computer and/or smartphone, and the ability to comprehend technology.

Graph 1: Growth of Telemedicine Utilization During the COVID-19 Pandemic (Line Graph)



This line graph shows the rapid increase in the utilization of telemedicine services during the COVID-19 pandemic, reflecting the shift in healthcare delivery models and highlighting its expanding role in modern healthcare(Alhassan & Ahmed 2016; Alzyoud et al., 2024; Mohammad et al., 2022; Rahamneh et al., 2023)..

Drug Safety

Pharmacovigilance Systems

Pharmacovigilance, therefore, has a central responsibility of monitoring and assessing the safety of drug products after these have been approved for usage. With the new strategies of administration involving more than one drug in combination and other developments that involve more and more comprehensive drug regimens, there is no better time than this when appropriate monitoring tools have become paramount. Pharmacovigilance systems assist in collecting and reporting information on ADRs and the safety profile of medicines over the long term. These systems are managed by regulatory bodies, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), to ensure that the drugs are safe throughout their use despite having received approval for sale. These systems are essential in coming up with risk profiles for new drugs, and they help the providers to know the safety aspects of the drugs that they provoke.

Comparison of Global Pharmacovigilance Systems

Adverse Drug Reactions (ADR)

Adverse drug reactions are still a problem within healthcare organizations because of the advancement in the development of more complicated structures of drug regimens. New systems in pharmacovigilance are comprised of AI and real-time monitoring to enable the early identification of ADRs. Machine learning is also being used to learn about the patient's profile and genetic disposition, history of sickness, and any other factors with the aim of being able to tell when the patient is most likely to have an allergic reaction. Such

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

developments are enabling healthcare institutions to cut risks and, in the process, offer safer treatments to patients. However, there still exists a major problem of underreporting of ADRs since some patients may never mention their side effects or symptoms. Improving the systems that capture ADRs and developing a better ability to report them will be crucial in the future development of drug safety.

Number of Reported Adverse Drug Reactions in the Last Decade (Bar Chart)



This bar chart shows the increase in reported adverse drug reactions over the past decade, highlighting the growing need for better monitoring systems and more effective reporting mechanisms to ensure patient safety(Mackey & Nayyar 2016; Al-Azzam et al., 2023; Al-Shormana et al., 2022; Al-E'wesat et al., 2024)..

This At the same time, this literature review also describes the challenges in developing effective treatment and patient care models and improving pharmaceutical safety systems. Privatization, the development of the concept of the individualized approach to patients, the broad use of telemedicine, and advancements in systems of pharmacovigilance also help to strengthen patient care and safety. However, the equitable reinvention of these advancements is still challenging, and the criticality of the existing concerns, such as global safety monitoring of drugs, is still vital. It will be important for healthcare and other stakeholders that future investigation and development occur to respond to these issues and enhance healthcare convergence and delivery in the world.

Methods

This review evaluates information collected from several scholarly articles, clinical articles, and pharmacological reports in light of the current status of drug development, strategies in patient handling, and security legislation. The first was the use of questionnaire data from peer-reviewed journal articles, case studies, and institutional reports. Secondary data involved pharmaceutical industry reports and online search databases such as PubMed and Scopus to capture the deviation of innovative pharmaceutical inventions and patients' attention.

Results and Findings:

Pharmaceutical Advancements and Outcomes:

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

The able and fast advancement of personalized medicines and precision therapies, or rather targeted treatments, has altered the treatment paradigms, especially in cancer. Cytotoxic drugs therapeutically used in cancer have been helpful; nevertheless, they are associated with several undesirable effects as a result of their lack of selectivity. However, molecularly targeted drugs, such as those used in treating genetic mutations, have seen enhanced patient survivability. For example, drugs to treat breast cancer-specific to the HER2 mutation, such as trastuzumab (Herceptin), are very effective in increasing survival rates. With discoveries of genetic mutations such as HER2 in breast cancer, BRAF in melanoma, and EGFR in lung cancer, it is possible to create therapies targeting specific mutations without harm to other healthy cells, hence developing minimal invasions and side effects.

Besides oncology, new approaches based on gene therapy have appeared as a treatment for previously uncontrollable and incurable genetic diseases. For instance, gene therapy treatment strategies for sickle cell anemia have shown early good results in clinical research endeavors, as these may offer an opportunity to cure this inherited disease. These therapies entail altering the patient's cells to edit genetic diseases. In the instance of sickle cell disease, CRISPR has been applied in the editing of the hemoglobin gene, and it has been successful. Acquiring these new potentialities signals a new epoch in the treatment of hereditary disorders that, otherwise, have no curative remedy.

In addition, progress is being made not only in treatments of genetic diseases inherited through generations but also in gene therapies. New-generation gene therapies are now planned for human trials for diseases such as muscular dystrophy, cystic fibrosis, and hemophilia. Further research into genetic therapies is likely to identify additional applications, providing the public with effective care for extensive diseases and disorders for which there are no known cures at present.

Patient-Centered Care Impact:

The incorporation of PCM into systems of care delivery has brought a shift in behavior in the determination of adherence to treatment and results. Patient-centered care focuses on the involvement of the patients and entails timely consultation between patients and healthcare providers in treatment planning. It has been most useful in the case of chronic ailments whose treatment requires the patient to go through continuous treatment. When patients are involved in the decision-making process and understand their treatment plans, they are fully compliant with suggested treatment regimes(Mackey & Nayyar 2016).. For instance, in oncology, decision-making on genetic testing empowers the client by making endogenous treatment more available, increasing client outcomes and satisfaction.

Aside from shared decision-making, patient-centered care has been effective in improving chronic disease management due to the enhanced adoption of digital health solutions. People are currently using wearable technologies and mobile applications to engage in the management of their health. These tools can assist patients with chronic diseases like hypertension, diabetes, or arrhythmia in monitoring blood pressure, glucose, and pulse levels remotely and sharing relevant data through available user interfaces with the doctors immediately. Telemedicine implemented during the COVID-19 pandemic has also supported patient-centered care by offering patients a less cumbersome way to access health care at central or standard points, mainly in rural or underprivileged areas. Such a concept as telemedicine enables patients to consult with doctors without actually having to travel sometimes long distances to see them, especially in regions with poor medical equipment.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

In addition, the advancement of patient engagement technologies, such as patient portals and EHR, has enhanced patient-physician interaction, leading to improved and appropriate coordination. These innovations further enhance the patient-centered care model based on shared decision-making by patients for their treatment. These tools will keep on improving as patient engagement is expected to rise higher, resulting in a boost in the patient's health.

Drug Safety

There has been improvement in the systems that are used in alerting the safety of the drugs once they have been approved for use. Thus, with the development of complex medical regimens, the uninterrupted stability of medicines is one of the most important goals. The overall surveillance process of medicines, which is pharmacovigilance, entails the reception, studying, and learning of side effects known as adverse drug reactions to ensure that the masses can use the drugs safely. The last decade has provided noticeable progress in using artificial intelligence and machine learning for the recognition and documentation of ADRs. Big data can be collected for each patient and then processed through AI algorithms to reveal trends or signals of emerging danger in a manner that no human could reasonably keep track of. These technologies make the risks more observable and easier to detect, thus helping in the case of high-risk drugs or new treatments with scarce evidence from clinical trials.

However, research has shown that there are still hurdles in getting the ADRs reported and exactly measured. In implementing routine reporting, under-reporting of ADRs is often experienced because patients sometimes do not report side effects. At the same time, some healthcare providers may not notice other forms of adverse reactions. However, a long-term, continuous safety assessment of drug consequences in real-life situations cannot be easily conducted, mainly because patients do not always adhere to the set medical regimen or may take time before developing symptoms(Mody et al., 2020).. Moreover, AI is not fully mature in the area of pharmacovigilance, and its greatest potential is probably not yet fully exploited. This, coupled with continuous research aimed at enhancing the use of artificial intelligence in identifying ADR, enhanced reporting amongst healthcare practitioners, and better relationships between healthcare providers, regulatory authorities, and drug manufacturers or distributors, will help in enhancing drug safety surveillance.

Another advancement in drug safety is the coming up of other regulatory measures, such as REMS, in the United States. REMS aims to minimize the risks associated with the use of specific high-risk drugs to the extent that other measures to restrict their availability and use will have to be put in place. These programs assist in guaranteeing that those patients who need high-risk drugs are well-supervised and informed about side effects. REMS programs have proven to be effective in preventing risks related to particular

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

medications; however, there are difficulties in making sure that doctors and consumers grasp and follow security measures.

All in all, innovation in various spheres of medicine, as well as learning patient needs or concerns over the revenues of pharmaceutical companies and improving the systems of drug scrutiny, have been paving the way to the changes. Advanced treatment, diagnosis, and patient engagement methodologies like precision medicines, gene therapies, and the like help in enhancing the overall patient experience and health. Nonetheless, the difficulties faced in monitoring drug safety, the recurrence of underreporting of ADRs, and guaranteeing rational distribution of newer treatment modalities underline the more than ever necessity for constant refinement of healthcare systems across the globe (Parekh et al., 2016).. Further developments in research and developments are required if these potential challenges are to be met and if patients are going to continue to receive improved, safer, and effective treatment.

Discussion

Impact of Pharmaceutical Advancements

Thanks to the advances in biotechnology, so-called personalized medicine, and gene therapies, numerous advances have been made in the treatment of diseases such as cancer and genetic diseases. Nevertheless, the cost of these therapies is still a critical factor in their availability and utility, especially in LAMICs(Katoue & Schwinghammer 2020).. The changes in regulatory approval of new drugs are still in progress, and organizations such as the FDA and EMA are striving to approve new drugs to treat breakthrough therapies.

Challenges in Patient-Centered Care

The PCPCC suggests that patient-centered care models have led to better health outcomes, but there remain the challenges as follows: This indicates that while telemedicine works under many conditions, it has several limitations concerning patients' IT competence, the availability of internet connection, and state policies(Bakshi et al., 2020).. Moreover, these models should be incorporated into already practiced models of healthcare, and this is a challenge, mainly in terms of logistics and finance in developing countries.

Drug Safety and Regulatory Challenges

The complexity of current treatments demands a sound pharmacovigilance program. The adoption of pharmacovigilance systems all over the world has enhanced drug safety but has gaps such as underreporting and real-time monitoring(Bakshi et al., 2020).. Moreover, ADRs remain a major threat since there is increased development of new and complicated treatment regimens.

Conclusions

Pharmacological developments, the approach to patients, and the rules aimed at the protection of medicinal products are quite interdependent and, in fact, are part of an exclusively solid triangle that has a significant impact on contemporary medicine. Despite the progress achieved in the areas of drug discovery and realization of patient-centric models and safety tracking, issues like the availability of novel therapies, the application of innovative technologies in the treatment processes, and the creation of effective and integrated methods of pharmacovigilance are still the pressing ones. The future of healthcare is in developing the continued advancement of technology in operations and equal access and precautions to ensure the proper safety of the patients.

There are two broad categories of health problems: infectious diseases and non-communicable diseases (or disease conditions).

Recommendation

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253

1. Enhancing Access to Personalized Medicine: Currently, policymakers should pay special attention to the affordability of personalized medicine and the issue of distributing therapeutic approaches to patients in need in remote areas.

2. Improving Patient-Centered Care Implementation: Health care must invest in its human resources to strengthen the capability of providers to deliver patient-centered health care that includes effective use of digital health technologies.

3. Strengthening Pharmacovigilance: Further, more efforts should be directed toward strengthening global pharmacovigilance systems, incorporating the use of artificial intelligence and machine learning to increase the rate at which ADRs are identified and increasing reporting currentness.

References

Al-Azzam, M. A. R., Alrfai, M. M., Al-Hawary, S. I. S., Mohammad, A. A. S., Al-Adamat, A. M., Mohammad, L. S., Al-hourani, L. (2023). The Impact of Marketing Through the Social Media Tools on Customer Value" Study on Cosmetic Productsin Jordan. In Emerging Trends and Innovation in Business and Finance (pp. 183-196). Singapore: Springer Nature Singapore.

Al-E'wesat, M.S., Hunitie, M.F., Al sarayreh, A., Alserhan, A.F., Al-Ayed, S.I., Al-Tit, A.A., Mohammad. A.A., Al-hawajreh, K.M., Al-Hawary, S.I.S., Alqahtani, M.M. (2024). Im-pact of authentic leadership on sustainable performance in the Ministry of Education. In: Hannoon, A., and Mahmood, A. (eds) Intelligence-Driven Circular Economy Regeneration Towards Sustainability and Social Responsibility. Studies in Computational Intelligence. Springer, Cham. Forthcoming.

Alhassan, A. M., & Ahmed, Q. U. (2016). Averrhoa bilimbi Linn.: A review of its ethnomedicinal uses, phytochemistry, and pharmacology. Journal of pharmacy and Bioallied sciences, 8(4), 265-271. https://journals.lww.com/jpbs/fulltext/2016/08040/averrhoa_bilimbi_linn___a_review_of_its.1.aspx

Al-Hawary, S. I. S., Mohammad, A. S., Al-Syasneh, M. S., Qandah, M. S. F., Alhajri, T. M. S. (2020). Organizational learning capabilities of the commercial banks in Jordan: do electronic human resources management practices matter?. International Journal of Learning and Intellectual Capital, 17(3), 242-266. https://doi.org/10.1504/IJLIC.2020.109927

Al-Husban, D. A. A. O., Al-Adamat, A. M., Haija, A. A. A., Al Sheyab, H. M., Aldai-hani, F. M. F., Al-Hawary, S. I. S., Mohammad, A. A. S. (2023). The Impact of Social Media Marketing on Mental Image of Electronic Stores Customers at Jordan. In Emerging Trends and Innovation in Business And Finance (pp. 89-103). Singa-pore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6101-6_7

Al-Nawafah, S., Al-Shorman, H., Aityassine, F., Khrisat, F., Hunitie, M., Mohammad, A., Al-Hawary, S. (2022). The effect of supply chain management through social media on competitiveness of the private hospitals in Jordan. Uncertain Supply Chain Management, 10(3), 737-746. http://dx.doi.org/10.5267/j.uscm.2022.5.001

Alolayyan, M.., Al-Hawary, S. I.., Mohammad, A. A., Al-Nady, B. A. (2018). Banking Service Quality Provided by Commercial Banks and Customer Satisfaction. A structural Equation Modelling Approaches. International Journal of Productivity and Quality Management, 24(4), 543–565. https://doi.org/10.1504/IJPQM.2018.093454

Al-Shormana, H., AL-Zyadat, A., Khalayleh , M., Al- Quran, A. Z., Alhalalmeh, M. I., Mohammad, A., Al-Hawary, S. (2022). Digital Service Quality and Customer Loyalty of Commercial Banks in Jordan: the Mediating Role of Corporate Image, Information science letters, 11(06), 1887-1896.

Alula, M. T., Mengesha, Z. T., & Mwenesongole, E. (2018). Advances in surface-enhanced Raman spectroscopy for analysis of pharmaceuticals: A review. Vibrational Spectroscopy, 98, 50-63. https://www.sciencedirect.com/science/article/pii/S0924203118300924

Alzyoud, M., Hunitie, M.F., Alka'awneh, S.M., Samara, E.I., Bani Salameh, W.M., Abu Haija, A.A., Al-shanableh, N., Mohammad, A.A., Al-Momani, A., Al-Hawary, S.I.S. (2024). Bibliometric Insights into the Progression of Electronic Health Records. In: Hannoon, A., and Mahmood, A. (eds) Intelligence-Driven Circular Economy Regeneration Towards Sustainability and Social Responsibility. Studies in Computational Intelligence. Springer, Cham. Forthcoming.

Aspinall, S. L., Sales, M. M., Good, C. B., Calabrese, V., Glassman, P. A., Burk, M., ... & Cunningham, F. E. (2016). Pharmacy benefits management in the Veterans Health Administration revisited: a decade of advancements, 2004-2014. Journal of managed care & specialty pharmacy, 22(9), 1058-1063. https://www.jmcp.org/doi/abs/10.18553/jmcp.2016.22.9.1058

Bakshi, H., Nagpal, M., Singh, M., Dhingra, G. A., & Aggarwal, G. (2020). Treatment of psoriasis: a comprehensive review of entire therapies. Current drug safety, 15(2), 82-104. https://www.ingentaconnect.com/content/ben/cds/2020/00000015/00000002/art00003

Cui, P., & Wang, S. (2019). Application of microfluidic chip technology in pharmaceutical analysis: A review. Journal of pharmaceutical analysis, 9(4), 238-247. https://www.sciencedirect.com/science/article/pii/S2095177918305094

Eldahamsheh, M.M., Almomani, H.M., Bani-Khaled, A.K.,Al-Quran, A.Z., Al-Hawary, S.I.S& Mohammad, A.A (2021). Factors Affecting Digital Marketing Success in Jordan . International Journal of Entrepreneurship , 25(S5), 1-12.

Fisher, A. C., Lee, S. L., Harris, D. P., Buhse, L., Kozlowski, S., Yu, L., ... & Woodcock, J. (2016). Advancing pharmaceutical quality: An overview of science and research in the US FDA's Office of Pharmaceutical Quality. International

journal of pharmaceutics, 515(1-2), 390-402. https://www.sciencedirect.com/science/article/pii/S0378517316310031

Hill, J. D., Hill, J. M., & Gentile, N. J. (2016). A review of state pharmacist collaborative practice laws. American Journal of Health-System Pharmacy, 73(18), 1467-1472. https://academic.oup.com/ajhp/article-abstract/73/18/1467/5101636

Jayaraman, P. P., Forkan, A. R. M., Morshed, A., Haghighi, P. D., & Kang, Y. B. (2020). Healthcare 4.0: A review of frontiers in digital health. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 10(2), e1350. https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/widm.1350

Jose, P. A., & GV, P. C. (2018). 3D printing of pharmaceuticals–a potential technology in developing personalized medicine. Asian journal of pharmaceutical research and development, 6(3), 46-54. http://ajprd.com/index.php/journal/article/view/375

Kanakaraju, D., Glass, B. D., & Oelgemöller, M. (2018). Advanced oxidation process-mediated removal of pharmaceuticals from water: A review. Journal of environmental management, 219, 189-207. https://www.sciencedirect.com/science/article/pii/S0301479718304912

Katoue, M. G., & Schwinghammer, T. L. (2020). Competency-based education in pharmacy: A review of its development, applications, and challenges. Journal of evaluation in clinical practice, 26(4), 1114-1123. https://onlinelibrary.wiley.com/doi/abs/10.1111/jep.13362

Knoer, S. J., Eck, A. R., & Lucas, A. J. (2016). A review of American pharmacy: education, training, technology, and practice. Journal of pharmaceutical health care and sciences, 2, 1-7. https://link.springer.com/article/10.1186/s40780-016-0066-3

Mackey, T. K., & Nayyar, G. (2016). Digital danger: a review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies. British medical bulletin, 118(1), 110-126. https://academic.oup.com/bmb/article-abstract/118/1/110/1744779

Miller, T. H., Bury, N. R., Owen, S. F., MacRae, J. I., & Barron, L. P. (2018). A review of the pharmaceutical exposome in aquatic fauna. Environmental pollution, 239, 129-146. https://www.sciencedirect.com/science/article/pii/S0269749117352375

Mody, H., Ramakrishnan, V., Chaar, M., Lezeau, J., Rump, A., Taha, K., ... & Ait-Oudhia, S. (2020). A review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clinical Pharmacology in Drug Development, 9(8), 896-909. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/cpdd.879

Mohammad, A. A. S., Alolayyan, M. N., Al-Daoud, K. I., Al Nammas, Y. M., Vasudevan, A., & Mohammad, S. I. (2024a). Association between Social Demographic Factors and Health Literacy in Jordan. Journal of Ecohumanism, 3(7), 2351-2365.

Mohammad, A. A. S., Al-Qasem, M. M., Khodeer, S. M. D. T., Aldaihani, F. M. F., Alserhan, A. F., Haija, A. A. A., ... & Al-Hawary, S. I. S. (2023b). Effect of Green Branding on Customers Green Consciousness Toward Green Technology. In Emerging Trends and Innovation in Business and Finance (pp. 35-48). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6101-6_3

Mohammad, A. A. S., Barghouth, M. Y., Al-Husban, N. A., Aldaihani, F. M. F., Al-Husban, D. A. A. O., Lemoun, A. A. A., ... & Al-Hawary, S. I. S. (2023a). Does Social Media Marketing Affect Marketing Performance. In Emerging Trends and Innovation in Business and Finance (pp. 21-34). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6101-6_2

Mohammad, A. A. S., Khanfar, I. A., Al Oraini, B., Vasudevan, A., Mohammad, S. I., & Fei, Z. (2024b). Predictive analytics on artificial intelligence in supply chain optimization. Data and Metadata, 3, 395-395.

Mohammad, A., Aldmour, R., Al-Hawary, S. (2022). Drivers of online food delivery orientation. International Journal of Data and Network Science, 6(4), 1619-1624. http://dx.doi.org/10.5267/j.ijdns.2022.4.016

Muheem, A., Shakeel, F., Jahangir, M. A., Anwar, M., Mallick, N., Jain, G. K., ... & Ahmad, F. J. (2016). A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharmaceutical Journal, 24(4), 413-428. https://www.sciencedirect.com/science/article/pii/S1319016414000590

Parekh, D., Kapupara, P., & Shah, K. (2016). Digital pharmaceutical marketing: A review. Research Journal of pharmacy and technology, 9(1), 108-112. https://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=9&issue=1&article=017

Rahamneh, A., Alrawashdeh, S., Bawaneh, A., Alatyat, Z., Mohammad, A., Al-Hawary, S. (2023). The effect of digital supply chain on lean manufacturing: A structural equation modelling approach. Uncertain Supply Chain Management, 11(1), 391-402. http://dx.doi.org/10.5267/j.uscm.2022.9.003

Reddy, R. D. P., & Sharma, V. (2020). Additive manufacturing in drug delivery applications: A review. International Journal of Pharmaceutics, 589, 119820. https://www.sciencedirect.com/science/article/pii/S037851732030805X

Shah, M., Peterson, C., Yilmaz, E., Halalmeh, D. R., & Moisi, M. (2020). Current advancements in the management of spinal cord injury: A comprehensive review of literature. Surgical neurology international, 11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969375/

Singh, R. K., Kumar, R., & Kumar, P. (2016). Strategic issues in pharmaceutical supply chains: a review. International Journal of Pharmaceutical and Healthcare Marketing, 10(3), 234-257. https://www.emerald.com/insight/content/doi/10.1108/IJPHM-10-2015-0050/full/html

White, C. M. (2019). A review of human studies assessing cannabidiol's (CBD) therapeutic actions and potential. The Journal of Clinical Pharmacology, 59(7), 923-934. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1387

Zylberberg, C., & Matosevic, S. (2016). Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug delivery, 23(9), 3319-3329. https://www.tandfonline.com/doi/abs/10.1080/10717544.2016.1177136

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 5256 – 5266
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.5253